A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study
The current Rethinking Clinical Trials (REaCT) trial will compare two schedules(12- vs.
4-weekly) of bone-targeting agents (BTAs) to evaluate quality of life, pain and skeletal
events within the Canadian Health Care System. This study will use an "integrated consent
model" that involves "oral consent" rather than a written informed consent writing process
as the study is comparing standard schedules and not a new administration schedule.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society